Source:http://linkedlifedata.com/resource/pubmed/id/20686253
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2010-8-5
|
pubmed:abstractText |
3-Methyl-1-phenyl-2-pyrazolin-5-one (edaravone, 1), known as a potent free radical scavenger, has been developed as a medical drug for the treatment of acute cerebral infarction. With the aim of developing radiotracers for imaging free radicals in vivo, 1-(3'-[(125)I]iodophenyl)-3-methy-2-pyrazolin-5-one ((125)I-2) was synthesized by two methods, via isotopic exchange and interhalogen exchange under solvent-free conditions, in which iodo- and bromo-derivatives were used as labeling precursors, respectively. After HPLC purification, (125)I-2 was obtained in modest isolated radiochemical yields (ca. 20%) with high radiochemical purities by both methods. The former gave specific activities of 0.2-0.6 kBq/micromol, whereas the latter approach achieved specific activities of more than 0.14 GBq/micromol. On attempting to prepare an injectable formulation for (125)I-2 with high specific activity, its radiochemical purities dropped to about 60-70%. Unlabeled analog 2 was found to have lipophilic and antioxidant properties similar to edaravone. Intravenous injection of (125)I-2 with low specific radioactivity into normal mice showed signs of distribution profiles similar to reported results for (14)C-labeled edaravone in normal rats.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1347-5223
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
58
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1020-5
|
pubmed:dateRevised |
2011-3-8
|
pubmed:meshHeading |
pubmed-meshheading:20686253-Animals,
pubmed-meshheading:20686253-Antioxidants,
pubmed-meshheading:20686253-Antipyrine,
pubmed-meshheading:20686253-Drug Stability,
pubmed-meshheading:20686253-Male,
pubmed-meshheading:20686253-Mice,
pubmed-meshheading:20686253-Mice, Inbred ICR,
pubmed-meshheading:20686253-Molecular Structure,
pubmed-meshheading:20686253-Pyrazolones,
pubmed-meshheading:20686253-Solubility,
pubmed-meshheading:20686253-Tissue Distribution
|
pubmed:year |
2010
|
pubmed:articleTitle |
1-(3'-[125I]Iodophenyl)-3-methy-2-pyrazolin-5-one: preparation, solution stability, and biodistribution in normal mice.
|
pubmed:affiliation |
Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|